Numares Health

Numares Health is a privately held diagnostics company based in Regensburg, Germany, founded in 2008. It has developed the AXINON® system, a first-of-its-kind modular diagnostic platform that integrates NMR hardware, proprietary Magnetic Group Signaling (MGS®) software, and AI-driven test algorithms to provide multiplexed metabolic profiling. The company is commercial-stage with an FDA-cleared test for cardiovascular risk (LDL-p) and CE-marked tests for kidney function and cardiovascular assessment in the EU, while also developing tests for liver cancer detection. Its technology aims to displace traditional single-analyte tests with more informative, multi-parameter metabolic signatures.

AXINON® system: A modular, software-based clinical diagnostics platform integrating nuclear magnetic resonance (NMR) spectroscopy hardware, a proprietary Magnetic Group Signaling (MGS®) processor for standardization, and AI/ML-driven test algorithms to generate diagnostic results from multiplexed metabolic signatures.

Numares competes in the broad metabolomics and specialized diagnostics space. Direct competitors include companies like Bruker (NMR systems) and Nightingale Health (NMR-based metabolomics services), as well as large IVD players like Abbott, Roche, and Siemens that dominate standard cardiometabolic testing. Its differentiation lies in its FDA-cleared, fully standardized clinical NMR platform and specific diagnostic algorithms, rather than just providing raw metabolomic data.